Industry News
Now we're a global player: stem cell CEO
Australia's decision to back stem cell research with a $46.5 million grant would have international ramifications for local researchers, according to the head of the winning Centre of Excellence bid. [ + ]
Proteome Systems launches ProteomIQ, moves into Japan
Sydney-based company Proteome Systems' proteomics R&D system, ProteomIQ, has been launched on the market. [ + ]
New Zealand joins synchrotron project
A New Zealand representative is to join the Australian Synchrotron Project's scientific advisory committee, cementing a trans-Tasman link between users of the new facility. [ + ]
Trans-Tasman biotech collaborations sought
New Zealand's political leadership is declaring the Land of the Long White Cloud open for collaborative ventures with Australia's biotech sector. [ + ]
CEO, directors depart as Bio21 changes direction
The chief executive officer and three other directors have resigned from Bio21 following a restructure that has seen the company abandon its commercial focus. [ + ]
WEHI research suggests alternative MS treatment
Researchers at the Walter and Eliza Hall Institute have discovered that treatment with cytokine Leukaemia Inhibitory Factor (LIF) can reverse the loss of nerve cells in a mouse model of multiple sclerosis (MS). [ + ]
Australian microarray meeting - South Stradbroke Island
The 2nd Australian Microarray Meeting is to be held at Couran Cove Resort, Sth Stradbroke Island from July 24th to 26th 2002. The meeting will focus on show casing recent national and international advances in expression profiling and other microarray technologies.
[ + ]Stem cell opponents shocked by funding decision
Opponents of stem cell research taking part in consultative processes on draft legislation were shocked and surprised by the announcement that the Stem Cells and Tissue Repair consortium had won the Federal government's $46.5 million Centre of Excellence funding. [ + ]
Signs of new life at Vita Life
Troubled biopharmaceutical group Vita Life Sciences has warned shareholders not to expect much from the natural medicines arm of its business in the coming year. [ + ]
Biotron begins cancer detection assay trials
A new clinical diagnostic assay for prostate cancer detection is starting clinical trials at St Vincent's Clinic in Sydney. [ + ]
Academy admits ARC head Sara
Australian Research Council CEO Prof Vicki Sara has been admitted by special election as a fellow of the Australian Academy of Science, for her contribution to recent government reforms and initiatives. [ + ]
Stem cell bid wins $46.5m Centre of Excellence funding
A proposal to create a Centre for Stem Cells and Tissue Repair has won a $46.5 million Federal grant to create a national Biotechnology Centre of Excellence. [ + ]
Peptech upbeat despite half year loss
Australian biotechnology company Peptech posted a net loss of $4.6 million on Wednesday for the half-year ended March 31, 2002, but said that the progress of key patents in the US would guarantee meaningful new revenue streams going forward. [ + ]
Biotechs need to focus on early-stage R&D: experts
Australia's biotech sector needed to focus on improving early stage compound validation to reduce the exorbitant costs of project attrition, experts said yesterday. [ + ]
US cancer institute evaluating Peplin drug
The American National Cancer Institute is scheduling advanced appraisals of an Australian anti-cancer drug which has produced impressive results in preliminary trials. [ + ]